Clinerion was selected by the Swiss Personalized Health Network to be the backbone of its Federated Query System due to the nature of its patented federated cloud infrastructure, which allows patient data to remain inside the IT infrastructure and under the control of each hospital, while still allowing queries of anonymized and obfuscated patient data from other hospitals in the network.
The five university hospitals of Switzerland are:
The FQS allows researchers to verify the feasibility of their project by assessing whether suitable patient data for specific research questions exist at Swiss university hospitals. The available information in the system, currently more than 70 million data elements from over 450’000 patients, who have consented to the further use of their data for research purposes, is a subset of the clinical data of all five university hospitals.
The platform includes demographic data (age and gender), diagnosis (coded in ICD-10), procedures (coded in CHOP), medication (coded in ATC), laboratory tests (coded in LOINC) and laboratory test results with units (according to UCUM). Under the project lead of the SPHN Data Coordination Center (DCC) managed by the SIB Swiss Institute of Bioinformatics, the clinical partners harmonized and standardized the anonymized clinical information, making it available for federated queries via a common front-end.
The FQS uses a customized version of Patient Network Explorer, enabling researchers to search for fully anonymized clinical information across all five university hospitals, while allowing the hospitals to retain full control over their data. It fully complies with privacy requirements, since only aggregated search results are shared with users and small patient numbers are obfuscated to prevent potential re-identification.
Clinerion Patient Network Explorer Technology Used by the Swiss Personalized Health Network
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.